As a result of APR-246 treatment, ROS levels increase and GSH cellular stores become eroded, and the attenuated xCT expression, resulting from mut-p53-mediated NRF2 inhibition, further reduces the ability of cancer cells to cope with oxidative stress. The gene discussed is TP53; the disease is cancer.